RareStone’s narcolepsy therapy receives approval in China
The Chinese NMPA has granted approval for RareStone Group’s pitolisant to treat cataplexy in adult narcolepsy patients.
The Chinese NMPA has granted approval for RareStone Group’s pitolisant to treat cataplexy in adult narcolepsy patients.
What's Your Reaction?
